GeneDx to Participate in Upcoming Investor Conference

11/22/24 4:05:00 PM ET

Retail: Computer Software & Peripheral Equipment

Technology

Get the next $WGS alert in real time by email

GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET.

Live and archived webcasts will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (NASDAQ:WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241122395958/en/

Get the next $WGS alert in real time by email

Date	Price Target	Rating	Analyst
8/28/2024	$34.00	Equal Weight	Wells Fargo
7/10/2024	$43.00	Buy	Craig Hallum
6/3/2024	$21.00	Hold	Jefferies

GeneDx to Participate in Upcoming Investor Conference

Chat with this insight

Recent Analyst Ratings for $WGS

$WGS Leadership Updates

Live Leadership Updates

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

Anagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac Ro

$WGS Financials

Live finance-specific insights

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights

$WGS SEC Filings

SEC Form 144 filed by GeneDx Holdings Corp.

SEC Form 144 filed by GeneDx Holdings Corp.

SEC Form 144 filed by GeneDx Holdings Corp.

$WGS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$WGS Market Insights

Live Market Insights

Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

Casdin Capital, Llc bought $842,604 worth of shares (40,000 units at $21.07) (SEC Form 4)

Casdin Capital, Llc bought $3,424,989 worth of shares (170,000 units at $20.15) (SEC Form 4)

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing

Expert Ratings For GeneDx Hldgs

Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $28

$WGS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wells Fargo initiated coverage on GeneDx with a new price target

Craig Hallum initiated coverage on GeneDx with a new price target

Jefferies resumed coverage on GeneDx with a new price target

$WGS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form 4 filed by Director Ruch Joshua

Director Ryan Jason gifted 141,356 shares and sold $3,316,880 worth of shares (47,000 units at $70.57) (SEC Form 4)

Large owner Icahn School Of Medicine At Mount Sinai sold $10,393,723 worth of shares (147,141 units at $70.64), decreasing direct ownership by 5% to 2,719,692 units (SEC Form 4)

$WGS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$WGS Press Releases

Fastest customizable press release news feed in the world

Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

GeneDx to Participate in Upcoming Investor Conference

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Recent Analyst Ratings for
$WGS

$WGS
Leadership Updates

$WGS
Financials

$WGS
SEC Filings

$WGS
Insider Purchases

$WGS
Market Insights

$WGS
Analyst Ratings

$WGS
Insider Trading

$WGS
Large Ownership Changes

$WGS
Press Releases